IVSonance, a Praxis Center for Venture Development client, was awarded a $65,000 FuzeHub Manufacturing Grant to develop the first clinic-ready versions of its SOUND™ technology, which uses sound waves to automate a critical in vitro fertilization (IVF) procedure.
IVSonance is tackling issues in fertility treatment, as more than 75% of couples who need fertility treatment never receive IVF. Clinics are struggling to meet demand worldwide, and with SOUND™, IVSonance aims to give these labs the tools they need to gently and consistently automate the procedure, allowing them to see more patients.
Specifically, the technology is a standalone device that helps technicians remove cells from retrieved eggs to assess their maturity and prepare them for fertilization. SOUND™ aids embryologists in this very delicate process with engineered precision, giving them the tools they need to have more impact in the clinic itself.
IVSonance’s approach fits seamlessly into existing clinical procedures so that embryologists don’t have to make substantial changes to their existing workflows. This differentiates the startup from previous IVF automation attempts, which required complete, disruptive workflow transitions that patients, clinicians, administrators, and regulators did not find to be worth the inherent risks.
The $65,000 grant will help IVSonance develop the first clinic-ready versions of SOUND™, moving the technology closer to use in IVF clinics. By automating this critical procedure, IVSonance aims to help embryologists perform the process more gently and consistently while giving clinics the ability to serve more patients.
IVSonance was one of ten collaborative project awardees selected from a record-breaking pool of 59 applicants for FuzeHub’s 2026 Manufacturing Grants. The award will help the company continue advancing SOUND™ from an early-stage technology toward a tool that can make a meaningful impact in fertility treatment.